Search

Displaying results 6021 - 6030 of 10000 in total
  1. Drug

    Vindesine

    go.drugbank.com/drugs/DB00309
    ApprovedInvestigationalWithdrawn

    Vindesine is used extensively in chemotherapy protocols (antineoplastic combined chemotherapy protocols).

  2. Drug

    AZD3409

    go.drugbank.com/drugs/DB04893
    Experimental

    AZD3409 is a farnesyl-transferase inhibitor (FAR) indicated for the treatment of solid tumors. Phase I trials were initiated January 2003, and were ongoing as of February 2004. … As of February 2007 the development of AZD3409 had been discontinued.

  3. Drug

    Elacridar

    go.drugbank.com/drugs/DB04881
    Investigational

    Development is assumed to have been discontinued. … In many cases, the appearance of multidrug resistance in cancer is due to a change in expression of protein inhibitors. As of August 2007 elacridar was not listed on GSK's product pipeline.

  4. Drug

    Pipotiazine

    go.drugbank.com/drugs/DB01621
    ApprovedInvestigationalWithdrawn

    It is used for the maintenance treatment of chronic non-agitated schizophrenic patients. Symptoms of overdose include severe extrapyramidal manifestations, hypotension, lethargy and sedation.

  5. Drug

    Alcaftadine

    go.drugbank.com/drugs/DB06766
    Approved

    Alcaftadine is a H1 histamine receptor antagonist indicated for the prevention of itching associated with allergic conjunctivitis. This drug was approved in July 2010.

  6. Drug

    Oleoyl-estrone

    go.drugbank.com/drugs/DB04870
    Investigational

    Oleoyl-estrone (OE) is a fatty acid ester of estrone. This hormone occurs naturally and is found circulating in various animal species and humans. … Body protein loss is an unpleasant effect of fat loss by the restriction of calories, and studies show that this drug appears to avoid this effect.

  7. Drug

    alpha-Pyrrolidinononanophenone

    go.drugbank.com/drugs/DB05531
    Investigational

  8. Drug

    Conestat alfa

    go.drugbank.com/drugs/DB09228
    Approved

    Marketed as the product Ruconest (FDA), this drug is indicated for the treatment of acute attacks of hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency in adults. … The primary function of endogenous C1INH is to regulate the activation of the complement and contact system pathways.

    Products: RUCONEST 2100 U IV ENJEKSİYONLUK ÇÖZELTİ İÇİN TOZ İÇEREN FLAKON, 1 ADET
  9. Drug

    Galsulfase

    go.drugbank.com/drugs/DB01279
    ApprovedInvestigational

    Galsufase is a variant form of the polymorphic human enzyme N-acetylgalactosamine 4-sulfatase of recombinant DNA origin. Galsulfase is a glycoprotein with a molecular weight of approximately 56 kD. … Post-translational modification of Cys53 produces the catalytic amino acid residue Ca-formylglycine, which is required for enzyme activity and is conserved in all members of the sulfatase enzyme family

  10. Drug

    Ispinesib

    go.drugbank.com/drugs/DB06188
    Investigational